CARM · As filed with the SEC
Carisma Therapeutics income statement, by fiscal year
The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Collaboration revenues | 19,632 | 14,919 | — | — | — | — |
| Operating expenses: | ||||||
| Research and development | 59,673 | 74,125 | 38,594 | 25,312 | 29,191 | 24,663 |
| General and administrative | 22,138 | 29,525 | 39,787 | 29,393 | 14,302 | 12,208 |
| Restructuring charge | — | — | 11,764 | 5,528 | 0 | 0 |
| Intangibles impairment charge | — | — | 27,764 | 31,700 | 0 | 0 |
| Change in fair value of contingent consideration | — | — | (52,000) | (56,840) | (11,180) | 71,620 |
| Total operating expenses | 81,811 | 103,650 | 65,909 | 35,093 | 32,313 | 108,491 |
| Operating loss | (62,179) | (88,731) | (25,909) | (8,549) | (21,077) | (108,491) |
| Interest income | — | — | 1,854 | — | 224 | — |
| Other income (expense), net | — | — | 296 | (60) | (99) | 991 |
| Loss Before Taxes | — | — | (23,759) | (8,609) | (20,952) | (107,500) |
| Benefit (provision) from income taxes | — | — | 3,875 | 8,273 | (1,445) | 0 |
| Change in fair value of derivative liability | 0 | (84) | — | — | — | — |
| Interest income, net | 1,702 | 1,936 | — | — | — | — |
| Net loss | (60,477) | (86,879) | (19,884) | (336) | (22,397) | (107,500) |
| Deemed Dividend | — | — | 0 | 0 | (147) | 0 |
| Net loss attributable to common stockholders - basic | — | — | (19,884) | (336) | (22,544) | (107,500) |
| Net loss attributable to common stockholders - diluted | — | — | (19,884) | (336) | (22,544) | (107,500) |
| Share information: | ||||||
| Net loss per share of common stock, basic (in USD per share) | (1.46) | (2.59) | (0.10) | 0.00 | (0.19) | (1.18) |
| Net loss per share of common stock, diluted (in USD per share) | (1.46) | (2.59) | (0.10) | 0.00 | (0.19) | (1.18) |
| Weighted-average shares of common stock outstanding, basic (in shares) | 41,456,210 | 33,524,197 | 200,546,000 | 182,323,000 | 118,221,000 | 90,929,000 |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 41,456,210 | 33,524,197 | 200,546,000 | 182,323,000 | 118,221,000 | 90,929,000 |
| Comprehensive loss | ||||||
| Net loss | (60,477) | (86,879) | — | — | — | — |
| Unrealized gain on marketable securities | 0 | 440 | — | — | — | — |
| Less: reclassification to net loss of previous unrealized gain on marketable securities | 0 | (399) | — | — | — | — |
| Comprehensive loss | (60,477) | (86,838) | — | (336) | (22,397) | (107,500) |
| Total revenue | — | — | 40,000 | 26,544 | 11,236 | 0 |
| License and related revenue | — | — | — | 26,544 | 11,236 | 0 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.